SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
SparingVision raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for…
Press Release
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022 Paris, May…
SparingVision Announces Oral Presentation of SPVN06 Data at ASGCT 2022
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022 Paris, May 3, 2022 –…
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis…
SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference
SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference Paris, January 6…
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer…
SparingVision to Present at Upcoming Investor Conferences
SparingVision to Present at Upcoming Investor Conferences Paris, December 3, 2021 – SparingVision (or the…
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Cambridge, MA, and Paris, France– October 13, 2021 Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading…
SparingVision Conference Participation in H2 2021
SparingVision announces the scientific and investor conferences that its management team will be participating in…